Paul Choi
Stock Analyst at Goldman Sachs
(2.61)
# 2,095
Out of 5,242 analysts
107
Total ratings
50%
Success rate
2.37%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVS Corvus Pharmaceuticals | Initiates: Buy | $40 | $12.19 | +228.14% | 1 | Apr 17, 2026 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $5.97 | +101.01% | 4 | Feb 10, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $34.62 | +174.41% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $78.77 | +20.60% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $71.02 | -29.60% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $68.22 | +46.58% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $54.28 | +1.33% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $9.10 | -34.07% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $96.09 | -19.87% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $32.82 | -39.06% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $49.90 | -5.81% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $7 → $12 | $14.27 | -15.91% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $30.22 | -90.07% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $0.2153 | +3,615.75% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $11.87 | -57.88% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $54.68 | -4.90% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $8.88 | +136.49% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.13 | -4.15% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $241.34 | -6.77% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $11.91 | +59.53% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.00 | +375.00% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.31 | +1,808.40% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $8.85 | +1,820.90% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $6.99 | +14.45% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $154.67 | -12.72% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $69.49 | +331.72% | 2 | Mar 30, 2020 |
Corvus Pharmaceuticals
Apr 17, 2026
Initiates: Buy
Price Target: $40
Current: $12.19
Upside: +228.14%
REGENXBIO
Feb 10, 2026
Maintains: Neutral
Price Target: $14 → $12
Current: $5.97
Upside: +101.01%
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $34.62
Upside: +174.41%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $78.77
Upside: +20.60%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $71.02
Upside: -29.60%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $68.22
Upside: +46.58%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $54.28
Upside: +1.33%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $9.10
Upside: -34.07%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $96.09
Upside: -19.87%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $32.82
Upside: -39.06%
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $49.90
Upside: -5.81%
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $14.27
Upside: -15.91%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $30.22
Upside: -90.07%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $0.2153
Upside: +3,615.75%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $11.87
Upside: -57.88%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $54.68
Upside: -4.90%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $8.88
Upside: +136.49%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $3.13
Upside: -4.15%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $241.34
Upside: -6.77%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $11.91
Upside: +59.53%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.00
Upside: +375.00%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.31
Upside: +1,808.40%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $8.85
Upside: +1,820.90%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $6.99
Upside: +14.45%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $154.67
Upside: -12.72%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $69.49
Upside: +331.72%